- Arvinas (ARVN, Financial) to present VERITAC-2 Phase 3 trial results at 2025 ASCO Annual Meeting.
- Vepdegestrant, developed with Pfizer, shows promise as a first-in-class oral treatment for ER+/HER2- breast cancer.
- The presentation will be held on May 31, 2025, led by Dr. Erika P. Hamilton.
Arvinas, Inc. (ARVN) has announced that the results from its Phase 3 VERITAC-2 clinical trial will be featured as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study evaluates vepdegestrant, an investigational oral PROTAC estrogen receptor degrader, developed jointly with Pfizer, compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer.
The upcoming presentation, scheduled for May 31, 2025, will be delivered by Dr. Erika P. Hamilton from the Sarah Cannon Research Institute’s Breast Cancer Research Program. The presentation will provide pivotal data for vepdegestrant, showcasing its potential as a novel treatment option in breast cancer therapy.
Arvinas has collaborated globally with Pfizer to co-develop and co-commercialize vepdegestrant, with shared worldwide expenses and profits. The drug has received Fast Track designation by the U.S. FDA for treating adults with ER+/HER2- advanced or metastatic breast cancer who have previously undergone endocrine-based therapy.
With a market cap of $521.29 million, Arvinas continues to make strides in biotechnology through its innovative PROTAC platform, actively progressing multiple investigational drugs in development. The VERITAC-2 trial's results will potentially support regulatory filings and further advancement in medical conferences throughout 2025.
